Company: DMAAR
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-046061
Chunk: 120

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 4
Chunk 120
---
by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On January 29, 2025, we consummated the Initial
Public Offering of 20,000,000 Units at $10.00 per Unit, generating proceeds of $200,000,000. Clear Street LLC acted as sole book-running
manager of the Initial Public Offering. The securities in the offering were registered under the Securities Act on registration statement
on Form S-1 (No. 333-281170). The registration statement was declared effective on January 7, 2025 and the post-effective amendment to
the registration statement was declared effective on January 27, 2025.

Simultaneous with the consummation of the Initial
Public Offering, we consummated the private placement with the sponsor of 400,000 Private Placement Units at a price of $10.00 per unit,
generating total proceeds of $4,000,000. Each Private Placement Unit consists of one ordinary share and one right to receive one-eighth
(1/8) of one ordinary share upon the consummation of an initial business combination. The proceeds from the sale of the Private Placement
Units were added to the net proceeds from the Initial Public Offering held in the trust account. The issuance was made pursuant to the
exemption from registration contained in Section 4(a)(2) of the Securities Act.

On February 18, 2025, the underwriters exercised
their over-allotment option to purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross
proceeds of $30,000,000. In connection with the underwriters’ exercise of their over-allotment option, the Company also consummated
the sale of an additional 30,000 Private Placement Units at $10.00 per Private Unit, generating total proceeds of $300,000. A total of
$231,150,000 was deposited into the trust account.

We paid a total of $8,898,201, consisting of $1,150,000
of cash underwriting fees, $6,900,000 of deferred underwriting fees, and $848,201 of other offering costs and expenses related to the
Initial Public Offering.

For a description of the use of the proceeds generated
in